Posted by Michael Wonder on 10 Oct 2021
Brii Bio initiates submission of emergency use authorisation filing to U.S. FDA for BRII-196/BRII-198, its monoclonal antibody combination therapy for non-hospitalised COVID-19 patients at high risk of clinical progression to severe disease
8 October 2021 - Data supporting the EUA filing will be submitted to the FDA on a rolling basis with the ultimate goal of securing regulatory approval as soon as possible.
Brii Biosciences today announced the filing of an emergency use authorisation application for its investigational SARS-CoV-2 (virus that causes COVID-19 combination therapy, BRII-196/BRII-198 with the U.S. FDA.
